Cargando…
EHMTI-0090. Botox in the prevention of chronic migraine; comparing NICE criteria versus hull criteria for evaluating responder rate
Autores principales: | Zafar, H, Khalil, M, Ahmed, F |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4181874/ http://dx.doi.org/10.1186/1129-2377-15-S1-G2 |
Ejemplares similares
-
EHMTI-0102. Prospective analysis of the use of onabotulinumtoxina (botox®) In the treatment of chronic migraine; real-life data in 299 patients from hull, UK
por: Khalil, M, et al.
Publicado: (2014) -
EHMTI-0223. Botox in the prevention of chronic migraine; 18-months follow up outcome in 67 patients
por: Khalil, M, et al.
Publicado: (2014) -
Hull prospective analysis of Botulinum Toxin type A (Botox) use in the treatment of chronic migraine
por: Ahmed, F, et al.
Publicado: (2013) -
EHMTI-0146. Topiramate in migraine prevention
por: Ristic, S, et al.
Publicado: (2014) -
Prospective analysis of the use of OnabotulinumtoxinA (BOTOX) in the treatment of chronic migraine; real-life data in 254 patients from Hull, UK
por: Khalil, Modar, et al.
Publicado: (2014)